Primary information |
---|
ID | antitb_1213 |
Peptide Name | Lassomycin |
Sequence | GLRRLFADQLVGRRNI-CO2CH3 |
N-terminal Modification | Involved in Cyclic formation |
C-terminal Modification | Addition of Methyl ester |
Chemical Modification | Formation of an amide bond between N-terminal amine and the side chain carboxyl group of Asp8. |
Linear/ Cyclic | Cyclic |
Length | 16 |
Chirality | L |
Nature | Highly Basic |
Source | Natural |
Origin | Extracts from soil actinomycetes |
Species | Mycobacterium tuberculosis |
Strain | Mycobacterium tuberculosis resistant to INH, RIF, EMB, PZA, FQ (181) |
Inhibition Concentartion | MIC = 0.78 μg/ml or 0.41 μM |
In vitro/In vivo | In vitro |
Cell Line | Human NIH 3T3 and HepG2, erythrocytes |
Inhibition Concentartion | NA |
Cytotoxicity | Low cytotoxicty (IC50, 350 μg/ml) against human NIH 3T3 and HepG2 cells |
In vivo Model | None |
Lethal Dose | NA |
Immune Response | NA |
Mechanism of Action | Uncoupling ATPase from proteolytic activity |
Target | ClpC1 ATPase complex |
Combination Therapy | None |
Other Activities | Antibacterial (other actinobacteria, gram positive and gram negative bacteria) |
Pubmed ID | 24684906 |
Year of Publication | 2014 |
3-D Structure | NA |